Top Biotech Companies in Singapore (94)

Strong Revenue Growth: Recent results show a meaningful step‑up in 2025 revenue with double‑digit year‑over‑year growth and guidance pointing to continued double‑digit expansion into 2026. Feedback suggests performance was slightly ahead of prior guidance and supported by broad‑based demand across regions and customer segments.

Strong Market Position & Advantage: ONT is described as a clear leader in nanopore sequencing and a co‑leader in long‑reads, differentiated by portability, real‑time analysis, ultra‑long reads, and native DNA/RNA methylation detection. Flagship datasets and assemblies reinforce this positioning.

Market Expansion: Updates highlight accelerating adoption beyond academia into clinical, applied industrial and biopharma use cases, alongside growing high‑throughput deployments on PromethION. Feedback suggests growth was evident across major geographies and end‑markets with notable momentum in regulated and applied settings.

Strong Market Position & Advantage: Elekta is a top-tier radiotherapy vendor with category leadership in cranial stereotactic radiosurgery and a notable presence in high-field MR-guided therapy, reinforcing durable competitive standing. Recognition for oncology information systems further supports its positioning in cancer centers.

Innovation-Driven Growth: Recent launches such as Elekta Evo and the Elekta ONE software suite, alongside continued advancement of Unity MR‑Linac workflows, indicate a pipeline that is aiding orders and improving mix. These innovations underpin adaptive and image‑guided therapy strategies across the portfolio.

Resilient & Sustainable Growth: Book‑to‑bill ratios above 1.0 and low single‑digit constant‑currency sales growth point to steady underlying expansion. Improving adjusted margins in recent quarters suggest operational gains despite macro headwinds.

Strong Market Position & Advantage: Roche is the global leader in in‑vitro diagnostics and remains a top‑tier biopharma with a significant oncology footprint. The dual Pharmaceuticals–Diagnostics model is a strategic differentiator at scale.

Strong Revenue Growth: Group sales rose 7% at constant exchange rates in 2025 and 6% at CER in Q1 2026, with both divisions contributing. Guidance for 2026 indicates continued mid–single‑digit CER growth.

Profitability: Profitability improved in 2025 alongside sales, with higher IFRS net income and core EPS growth. Management pointed to capacity to keep investing while rewarding shareholders.

Strong Market Position & Advantage: The business is positioned as a global leader in eye care with meaningful share in contact lenses and one of the largest installed bases in ophthalmic surgical equipment, supporting durable demand across geographies. Scale across Vision Care and Surgical also supports recurring revenue via consumables tied to the installed base.

Resilient & Sustainable Growth: Revenue is described as growing year over year with guidance calling for continued mid-single-digit constant-currency sales growth into 2026, supported by steady demand for essential procedures like cataract surgery. The company is also positioned to outpace broader eye-care market growth expectations per the provided outlook.

Healthy Cash Flow: Cash generation is described as strong, with operating cash flow and free cash flow at sizable levels that support ongoing investment and shareholder returns. This cash profile provides resilience against near-term cost headwinds and funding for launches and efficiency programs.

Strong Market Position & Advantage: Colleagues are often seen as operating from a top-tier competitive position in applied, food, and environmental analytical markets, including a significant presence in food testing and leadership in multivendor lab services via OneSource. The large global installed base and asset footprint are portrayed as reinforcing defensibility and ongoing demand for services and support.

Innovation-Driven Growth: Colleagues are often seen as sustaining relevance through ongoing product launches and upgrades such as digital PCR systems, updated LIMS software, and new analytical platforms aimed at emerging needs like PFAS detection and battery applications. The continued cadence of new instruments and workflow solutions is positioned as a key growth lever alongside services and consumables.

Investor Backing & Capital Strength: Colleagues are often seen as supported by private-equity ownership under New Mountain Capital and described with a substantial valuation, suggesting access to capital and an explicit mandate to scale. Recent acquisitions (e.g., Covaris and Project Farma) are framed as capability-building moves consistent with a funded expansion strategy.

Strong Market Position & Advantage: Invisalign is broadly viewed as the clear leader in doctor‑directed clear aligners, reinforced by a large trained‑doctor base and an integrated digital workflow. Record Q4/FY 2025 volumes and revenue, alongside industry characterization as the market leader, support advantage durability.

Market Expansion: International regions (EMEA, Latin America, APAC) are cited as driving year‑over‑year volume growth, with contributions from teen/kids and adult segments and growing DSO/OSO channels. Continued gains outside North America align with guidance for additional growth into 2026.

Innovation-Driven Growth: An integrated platform spanning Invisalign, iTero scanners, and exocad software underpins a closed‑loop workflow that encourages adoption. Ongoing iTero Lumina upgrades and plans for directly 3D‑printed retainers/attachments in 2026 indicate a pipeline that can sustain future growth.

Strong Revenue Growth: 2025 results show total revenues up 10% to $36.8 billion and guidance for 2026 at $37.0–$38.4 billion signals continued top‑line expansion.

Diversified Revenue Streams: Company updates indicate a broad base with roughly 40 marketed products and 14 blockbusters in 2024, and in 2025 eighteen products reached record sales with notable growth from Repatha, TEZSPIRE, EVENITY, BLINCYTO, and rare‑disease brands.

Strong Market Position & Advantage: Evidence suggests Amgen is widely regarded as a leader among large‑cap biotechs with significant scale and an expanded rare‑disease footprint following the Horizon acquisition.

Strong Revenue Growth: Revenue is rising strongly, with 2024 up to $54.1B and continued momentum into 2025 alongside management’s stated 2030 ambition. The trend is broad‑based across oncology and biopharma, with repeated beats and reaffirmed guidance supporting durability.

Strong Market Position & Advantage: Market position is top‑tier globally by value and leadership is pronounced in oncology, where the company ranks among the top three by revenue with multiple anchor assets. Scale and execution in the U.S. and other key markets underline competitive advantage.

Innovation-Driven Growth: Pipeline and approvals are driving expansion, with multiple 2025 U.S. FDA wins for ADCs, an expanded first‑line label for Enhertu, and a deep ASCO 2025 presence across ADC, I/O, targeted agents, and SERD.

Strong Market Position & Advantage: Thermo Fisher’s scale and breadth—largest revenue in 2025 (~$44.6B), leadership across a moderately consolidated tools market, and a top‑tier market value—support clear category leadership. Third‑party benchmarking and peer comparisons (e.g., relative to Danaher) reinforce its platform advantage.

Diversified Revenue Streams: A broad, integrated portfolio spanning instruments, consumables, diagnostics, distribution, and biopharma services (PPD, Patheon) drives multiple revenue engines and customer stickiness. Recurring consumables/services and distribution contribute steady mix that helps smooth cycles.

Innovation-Driven Growth: Recent product launches (e.g., Glacios 3 Cryo‑TEM, TSQ Certis) and the NVIDIA collaboration to accelerate AI‑enabled and increasingly autonomous lab systems indicate continued innovation momentum. These initiatives position the platform to capture next‑gen workflow demand.